Second dimension

Fidelity BioSciences has placed a series A bet in Dimension Therapeutics and the biotech's liver-directed AAV gene therapies for hemophilia. The company already has pulled in $50 million in equity and partnership dollars and is looking to advance multiple products into the clinic.

Fidelity led last week's close of Dimension's $30 million series A round, joined by new investor OrbiMed. The company raised an undisclosed amount in an initial close with Fidelity in October...